|

68Ga-AAZTA-093 PET/CT: First-in-human Study

RECRUITINGEarly 1Sponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
PhaseEarly 1
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2024-04-01
Est. completion2024-07-01
Eligibility
Age18 Years – 90 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06437496

Summary

68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.

Eligibility

Age: 18 Years – 90 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* 68Ga-AAZTA-093 and 68Ga-PSMA-11/68Ga-PSMA-617 PET/CT within 1 week;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions2

CancerMalignant Neoplasm of Prostate

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.